Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
Switching patients with cancer from reference pegfilgrastim (Neulasta) to biosimilar pegfilgrastim (Udenyca) not only reduces the cost of prophylaxis treatment for chemotherapy-induced febrile neutropenia (FN) but also provides funds for adjuvant treatment, according to findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
Below is a summary of these findings.
Biosimilar Pegfilgrastim Cost-Effectiveness
A cost-efficiency analysis based on current average sales prices indicated potential cost savings per patient treated with biosimilar pegfilgrastim versus reference pegfilgrastim with or without the on-body injector (Onpro) ranged from $223 for 1 cycle to $1335 for 6 cycles.1
Study results from a panel of 20,000 patients with cancer showed that the savings generated from 1 cycle of pegfilgrastim prophylaxis with 10% of patients converted to the biosimilar would be $445,163. For 6 cycles of pegfilgrastim with 100% of patients using biosimilar pegfilgrastim, savings jumped to $26,709,788.
Based on single cycles of chemotherapy for the population cohort, the potential savings from biosimilar prophylaxis translate into expanded access of 115 additional doses at 10% conversion from the reference product and 1154 doses at 100% conversion.
The savings compounded over 6 cycles of chemotherapy could provide 692 additional doses of biosimilar pegfilgrastim at 10% conversion. If 100% of patients at risk of chemotherapy-induced FN switched, savings over 6 cycles could provide 6921 additional doses.
The number of patients needed to convert from the reference product to cover the cost of 1 additional dose of biosimilar pegfilgrastim is 18, according to the study.
Expanded Access to Adjuvant Therapy
Using the same payment-focused model, researchers expanded these potential savings of switching to the biosimilar from the reference product and extrapolated to the adjuvant chemotherapy (doxorubicin or cyclophosphamide) setting.2
If 10% of patients in the cohort of 20,000 converted to biosimilar pegfilgrastim, over 1 cycle of chemotherapy the same savings from the earlier study could pay for 1286 single cycles of additional chemotherapy. Additionally, 12,861 additional cycles would be generated if 100% of patients at risk of FN converted.
The savings over 6 cycles of chemotherapy could provide between 7717 additional cycles of doxorubicin/cyclophosphamide at 10% conversion to biosimilar pegfilgrastim in the chemotherapy-induced FN risk group and 77,166 cycles at 100% conversion.
Only 2 patients would be needed to convert to the biosimilar from reference pegfilgrastim to provide savings enough for 1 additional cycle of doxorubicin/cyclophosphamide.
“These savings could be reallocated to provide access to curative anti-neoplastic treatment on a budget-neutral basis, thus enhancing the value of cancer care to both payers and patients,” the investigators wrote.
For more from ASCO20 Virtual, visit our conference page.
References
1. Mcbride A, MacDonald K, Abraham I. Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis. Presented at ASCO20 Virtual; May 30-31, 2020. Abstract e19372. meetinglibrary.asco.org/record/190726/abstract.
2. Mcbride A, MacDonald K, Abraham I. Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer. Presented at ASCO20 Virtual; May 30-31, 2020. Abstract e19371. meetinglibrary.asco.org/record/190413/abstract.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.